ABOS

Acumen Pharmaceuticals, Inc. (ABOS) is a biotechnology company operating in the healthcare sector with a relatively small scale, employing 61 individuals and having a market capitalization of $119.94 million. The company's financial health is marked by significant losses, with a net income of -$133,351,000 and an EBITDA of -$138,170,000 over the trailing twelve months. This results in unprofitable margins across various metrics, including gross margin (0.0%), operating margin (0.0%), and profit margin (0.0%). The returns on equity (-85.9%) and assets (-42.2%) are also negative. Acumen's balance sheet reveals a debt-to-equity ratio of 33.09, indicating leverage, while the cash position stands at $126.61 million and total debt is $30.84 million. Acumen Pharmaceuticals' valuation metrics include a forward P/E ratio of -1.14, which may indicate overvaluation or significant growth prospects in the future. However, this assessment requires caution due to the company's negative earnings and lack of historical revenue data. The price-to-book ratio stands at 1.29, suggesting a relatively affordable stock from a book value perspective.